1
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
2
|
Ramdass B, Maliekal TT, Lakshmi S, Rehman
M, Rema P, Nair P, Mukherjee G, Reddy BK, Krishna S and
Radhakrishna Pillai M: Coexpression of Notch1 and NF kappaB
signaling pathway components in human cervical cancer progression.
Gynecol Oncol. 104:352–361. 2007. View Article : Google Scholar
|
3
|
Liu M, Wu H, Liu T, Li Y, Wang F, Wan H,
Li X and Tang H: Regulation of the cell cycle gene, BTG2, by miR-21
in human laryngeal carcinoma. Cell Res. 19:828–837. 2009.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Li JL, Sainson RC, Oon CE, Turley H, Leek
R, Sheldon H, Bridges E, Shi W, Snell C, Bowden ET, et al:
DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy
in vivo. Cancer Res. 71:6073–6083. 2011. View Article : Google Scholar : PubMed/NCBI
|
5
|
Capaccione KM and Pine SR: The Notch
signaling pathway as a mediator of tumor survival. Carcinogenesis.
34:1420–1430. 2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Ntziachristos P, Lim JS, Sage J and
Aifantis I: From fly wings to targeted cancer therapies: A
centennial for notch signaling. Cancer Cell. 25:318–334. 2014.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Bin Hafeez B, Adhami VM, Asim M, Siddiqui
IA, Bhat KM, Zhong W, Saleem M, Din M, Setaluri V and Mukhtar H:
Targeted knockdown of Notch1 inhibits invasion of human prostate
cancer cells concomitant with inhibition of matrix
metalloproteinase-9 and urokinase plasminogen activator. Clin
Cancer Res. 15:452–459. 2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Wang Z, Li Y, Banerjee S, Kong D, Ahmad A,
Nogueira V, Hay N and Sarkar FH: Down-regulation of Notch-1 and
Jagged-1 inhibits prostate cancer cell growth, migration and
invasion, and induces apoptosis via inactivation of Akt, mTOR, and
NF-kappaB signaling pathways. J Cell Biochem. 109:726–736.
2010.PubMed/NCBI
|
9
|
Yeh TS, Wu CW, Hsu KW, Liao WJ, Yang MC,
Li AF, Wang AM, Kuo ML and Chi CW: The activated Notch1 signal
pathway is associated with gastric cancer progression through
cyclooxygenase-2. Cancer Res. 69:5039–5048. 2009. View Article : Google Scholar : PubMed/NCBI
|
10
|
Chiaramonte R, Basile A, Tassi E,
Calzavara E, Cecchinato V, Rossi V, Biondi A and Comi P: A wide
role for NOTCH1 signaling in acute leukemia. Cancer Lett.
219:113–120. 2005. View Article : Google Scholar : PubMed/NCBI
|
11
|
Mirandola L, Comi P, Cobos E, Kast WM,
Chiriva-Internati M and Chiaramonte R: Notching from T-cell to
B-cell lymphoid malignancies. Cancer Lett. 308:1–13. 2011.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Weng AP, Ferrando AA, Lee W, Morris JP IV,
Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT and Aster
JC: Activating mutations of NOTCH1 in human T cell acute
lymphoblastic leukemia. Science. 306:269–271. 2004. View Article : Google Scholar : PubMed/NCBI
|
13
|
Chiaramonte R: Still puzzling Notch
signaling in B-cell malignancies. Leuk Res. 30:1331–1332. 2006.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Hubmann R, Schwarzmeier JD, Shehata M,
Hilgarth M, Duechler M, Dettke M and Berger R: Notch2 is involved
in the overexpression of CD23 in B-cell chronic lymphocytic
leukemia. Blood. 99:3742–3747. 2002. View Article : Google Scholar : PubMed/NCBI
|
15
|
Trøen G, Wlodarska I, Warsame A, Hernández
Llodrà S, De Wolf-Peeters C and Delabie J: NOTCH2 mutations in
marginal zone lymphoma. Haematologica. 93:1107–1109. 2008.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Egloff AM and Grandis JR: Molecular
pathways: Context-dependent approaches to Notch targeting as cancer
therapy. Clin Cancer Res. 8:5188–5195. 2012. View Article : Google Scholar
|
17
|
Leong KG and Karsan A: Recent insights
into the role of Notch signaling in tumorigenesis. Blood.
107:2223–2233. 2006. View Article : Google Scholar
|
18
|
Yin L, Velazquez OC and Liu ZJ: Notch
signaling: Emerging molecular targets for cancer therapy. Biochem
Pharmacol. 80:690–701. 2010. View Article : Google Scholar : PubMed/NCBI
|
19
|
Chu D, Li Y, Wang W, Zhao Q, Li J, Lu Y,
Li M, Dong G, Zhang H, Xie H and Ji G: High level of Notch1 protein
is associated with poor overall survival in colorectal cancer. Ann
Surg Oncol. 17:1337–1342. 2010. View Article : Google Scholar : PubMed/NCBI
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–8. 2001.
View Article : Google Scholar
|
21
|
Wang J, Wang C, Meng Q, Li S, Sun X, Bo Y
and Yao W: siRNA targeting Notch 1 decreases glioma stem cell
proliferation and tumor growth. Mol Biol Rep. 39:2497–2503. 2012.
View Article : Google Scholar
|
22
|
Ristorcelli E and Lombardo D: Targeting
Notch signaling in pancreatic cancer. Expert Opin Ther Targets.
14:541–552. 2010. View Article : Google Scholar : PubMed/NCBI
|
23
|
Jundt F, Anagnostopoulos I, Förster R,
Mathas S, Stein H and Dörken B: Activated Notch1 signaling promotes
tumor cell proliferation and survival in Hodgkin and anaplastic
large cell lymphoma. Blood. 99:3398–3403. 2002. View Article : Google Scholar : PubMed/NCBI
|
24
|
Liu ZJ, Xiao M, Balint K, Smalley KS,
Brafford P, Qiu R, Pinnix CC, Li X and Herlyn M: Notch1 signaling
promotes primary melanoma progression by activating
mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt
pathways and up-regulating N-cadherin expression. Cancer Res.
66:4182–4190. 2006. View Article : Google Scholar : PubMed/NCBI
|
25
|
Wang Z, Zhang Y, Li Y, Banerjee S, Liao J
and Sarkar FH: Down-regulation of Notch-1 contributes to cell
growth inhibition and apoptosis in pancreatic cancer cells. Mol
Cancer Ther. 5:483–493. 2006. View Article : Google Scholar : PubMed/NCBI
|
26
|
Espinoza I and Miele L: Notch inhibitors
for cancer treatment. Pharmacol Ther. 139:95–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
27
|
Jin R, Nakada M, Teng L, Furuta T, Sabit
H, Hayashi Y, Demuth T, Hirao A, Sato H, Zhao G and Hamada J:
Combination therapy using Notch and Akt inhibitors is effective for
suppressing invasion but not proliferation in glioma cells.
Neurosci Lett. 534:316–321. 2013. View Article : Google Scholar
|
28
|
Sivasankaran B, Degen M, Ghaffari A, Hegi
ME, Hamou F, Ionescu MC, Zweifel C, Tolnay M, Wasner M,
Mergenthaler S, et al: Tenascin C is a novel RBPJkappa induced
target gene for Notch signaling in gliomas. Cancer Res. 69:458–465.
2009. View Article : Google Scholar : PubMed/NCBI
|
29
|
Luo DH, Zhou Q, Hu SK, Xia YQ, Xu CC, Lin
TS, Pan YT, Wu JS and Jin R: Differential expression of Notch1
intracellular domain and p21 proteins, and their clinical
significance in gastric cancer. Oncol Lett. 7:471–478.
2014.PubMed/NCBI
|
30
|
Ramakrishnan V, Ansell S, Haug J, Grote D,
Kimlinger T, Stenson M, Timm M, Wellik L, Halling T, Rajkumar SV
and Kumar S: MRK003, a γ-secretase inhibitor exhibits promising in
vitro pre-clinical activity in multiple myeloma and non-Hodgkin's
lymphoma. Leukemia. 26:340–348. 2012. View Article : Google Scholar
|
31
|
Widmann C, Gibson S, Jarpe MB and Johnson
GL: Mitogen-activated protein kinase: Conservation of a
three-kinase module from yeast to human. Physiol Rev. 79:143–180.
1999.PubMed/NCBI
|
32
|
Zhou L, Wang DS, Li QJ, Sun W, Zhang Y and
Dou KF: Downregulation of the Notch signaling pathway inhibits
hepatocellular carcinoma cell invasion by inactivation of matrix
metalloproteinase-2 and -9 and vascular endothelial growth factor.
Oncology Reports. 28:874–882. 2012.PubMed/NCBI
|
33
|
Asnaghi L, Ebrahimi KB, Schreck KC, Bar
EE, Coonfield ML, Bell WR, Handa J, Merbs SL, Harbour JW and
Eberhart CG: Notch signaling promotes growth and invasion in uveal
melanoma. Clin Cancer Res. 18:654–665. 2012. View Article : Google Scholar : PubMed/NCBI
|
34
|
Pickering CR, Zhou JH, Lee JJ, Drummond
JA, Peng SA, Saade RE, Tsai KY, Curry JL, Tetzlaff MT, Lai SY, et
al: Mutational landscape of aggressive cutaneous squamous cell
carcinoma. Clin Cancer Res. 20:6582–6592. 2014. View Article : Google Scholar : PubMed/NCBI
|